Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Single-arm Study of Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (CKS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05846724
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:35.313223+00:00
Published At
2026-01-22T00:00:00+00:00
Record Updated At
2026-01-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Kaposi Sarcoma", "Classic Kaposi Sarcoma", "Refractory Kaposi Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-22"
protocolSection.identificationModule.nctId
"NCT05846724"
protocolSection.identificationModule.officialTitle
"A Phase II Single-arm Study of Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (CKS)"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Kaposi Sarcoma (protocolSection.conditionsModule.conditions)
  • Classic Kaposi Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Kaposi Sarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.